My ePortfolio Register   

ESMO 2017 /
Panitumumab triplet therapy in colorectal cancer

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 659
Rating:

Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany

Prof Geißler speaks with ecancer at ESMO 2017 about the VOLFI trial of FOLFOXIRI chemotherapy combined with panitumumab, an EGFR binding antibody, to treat RAS wildtype metastatic colorectal cancer.

He introduces the rationale of the trial, to investigate the impact of any monoclonal antibody with a FOLFOX based chemotherapy backbone, and notes the significant increase to response rates in both left and right-sided colorectal tumours.

Prof Geißler also notes the number of patients eligible for resection of secondary disease, and that the lack of improvement in PFS among trial patients is typical for metastatic colorectal cancer.

An essential consideration for panitumumab suitability will be patient fitness, as Prof Geißler notes the significant toxicity profile associated with the triplet combination.


ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence